New GERD drug tegoprazan tested in large real-world study
NCT ID NCT07678177
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study investigates the safety and symptom-relieving effects of the drug Tegoprazan (K-CAB) in adults with gastroesophageal reflux disease (GERD). Researchers will track how well the drug reduces heartburn and acid reflux after 4 weeks of use. The study includes over 5,000 participants and aims to provide real-world evidence on the drug's performance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tegoprazan (K-CAB)
- What this could lead to
- If successful, this could confirm Tegoprazan as a reliable treatment option for controlling GERD symptoms.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Individual responses to the drug can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERD (GASTROESOPHAGEAL REFLUX DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HK inno.N
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart bottle cap could reveal hidden missed doses in GERD patients
- Could a simple liquid barrier help nighttime heartburn sufferers sleep better?
- Can a diet and lifestyle program replace acid reflux pills after achalasia surgery?
- Fat cells injected into esophagus could tame reflux without surgery
- Could a simple gel soothe heartburn without drugs? new trial aims to find out
- New app aims to help GERD patients stick to treatment